This is a single-dose, non-randomised, open-label, parallel-group study.~All participants will receive a single oral dose of 5 mg zibotentan under fasted conditions and will be involved in the study for approximately 5 weeks.~Approximately 12 participants will be enrolled into each one of the 2 cohorts and receive the study intervention:~Cohort 1: 12 participants with moderate hepatic impairment and moderate renal impairment as assessed at Screening~Cohort 2: 12 healthy participants matched for age (± 10 years), gender, and BMI (± 20%) on a group level to participants in Cohort 1~The study will comprise of the following study periods:~A Screening Period of maximum 28 days (before dosing): participants will be screened for eligibility.~A Residential Period of 8 days: participants will be admitted to the study centre in the evening on Day~2, two days before administration of a single oral dose of zibotentan (Day 1). Participants will have final study assessments on Day 6 (120 hours post-dose) and will be discharged that day.
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.